pntd.0011910.g002.tif (529.27 kB)
Serological responses in patients with efficacious chemotherapy.
figure
posted on 2024-01-18, 18:41 authored by Manuel Abal, Virginia Balouz, Rosana Lopez, M. Eugenia Giorgi, Carla Marino, Cintia V. Cruz, Jaime Altcheh, Carlos A. BuscagliaA) Diagram showing direct comparison of α-Gal-ELISA and tELISA results in the fraction (n = 37) of α-Gal reactive patients. B) Kaplan-Meier curves showing the survival time for antibodies determined by tELISA (red; n = 59) and α-Gal-ELISA (green; n = 37) in T. cruzi-infected children. Median negativization values are indicated for each data set. Censored cases are indicated with filled circles. Log-rank (Mantel-Cox) analyses were performed to compare median time of negative seroconversion.
History
Usage metrics
Categories
Keywords
trypomastigotes surface coattechnical difficulties associatedprotective antibody responseprevious studies indicatedpatient negative seroconversionlinked immunosorbent assayincluded 39 nonbsa scaffold decorated83 months ];3 groups based>- infected mothersretrospective cohort studygal antigenic surrogateelisa may assistvs 60 monthsconventional serological tests>- infected childrentrypanosoma cruzi 4 %), αconventional serological methods3 %) patients>- infectedserological responsesconventional serologyvs 43treated childrenparasitological testscruzi infected infantsinfected individualsgroup 45 months4 years36 months23 months3 years3 daysxlink ">treatment initiationtreatment evaluationtools evaluatedtherapeutic responsestherapeutic markertermed ngpsynthetic αsuccessful treatmentsuboptimal seroprevalencestraightforward postshorten followseveral unitsroutine implementationproper evaluationprolonged persistencep novel toolneoglycoprotein consistingic 95house enzymehigher rateherein developedevery groupdisappears soondiagnostic needsdetailed analysiscontrol cohortchagas diseaseanalyzed separately31 days26 days16 years
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC